Key Metrics
3.3
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.66
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Indexed in the following public directories
-
Scopus
Topics Covered
- Clinical trial
- Interleukin
- Psoriasis
- Receptor antagonist
- Pretomanid
- Drug discovery
- Hydrochlorothiazide
- Macular degeneration
- Ocular hypertension
- Bruton's tyrosine kinase
- Secondary Myelofibrosis
- Ibrutinib
- Heart failure
- Spinal muscular atrophy
- Sorafenib
- Rheumatoid arthritis
- Apomorphine
- Remimazolam
- Bruton's tyrosine kinase inhibitor
- Fedratinib
Journal Specifications
| Overview | |
| Publisher | PROUS SCIENCE, SAU-THOMSON REUTERS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1964 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Drugs of Today ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Monoclonal antibodies for treatment of osteoporosis.
- 1 Mar 23
- Drugs of today (Barcelona, Spain : 1998)
-
Full paper
Mitapivat for sickle cell disease and thalassemia.
- 1 Mar 23
- Drugs of Today
-
Full paper
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
- 1 Mar 23
- Drugs of Today
-
Full paper
Cenegermin for the treatment of dry eye disease.
- 1 Mar 23
- Drugs of today (Barcelona, Spain : 1998)
-
Full paper
Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.
- 1 Mar 23
- Drugs of Today
-
Full paper
Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.
- 1 Mar 23
- Drugs of today (Barcelona, Spain : 1998)
Scite analysis
Powered by scite_
1.9k articles received 12.7k citations see all
- 199 Supporting
- 11,956 Mentioning
- 29 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 0 Corrections
- 0 Errata
- 0 Expression of Concern
FAQs
How long has Drugs of Today been actively publishing?
Drugs of Today has been in operation since 1964 till date.
What is the publishing frequency of Drugs of Today ?
Drugs of Today published with a Monthly frequency.
How many articles did Drugs of Today publish last years ?
In 2024, Drugs of Today published articles.
What is the eISSN & pISSN for Drugs of Today ?
For Drugs of Today,eISSN is 1699-4019 and pISSN is1699-3993.
What is Citescore for Drugs of Today ?
Citescore for Drugs of Today is 3.3.
What is SNIP score for Drugs of Today ?
SNIP score for Drugs of Today is 0.66.
Who is the publisher of Drugs of Today ?
PROUS SCIENCE, SAU-THOMSON REUTERS is the publisher of Drugs of Today.